JP Morgan Chase & Co. crosses the 5% threshold at ABIVAX

On September 29, 2025, JP Morgan Chase & Co. crossed the threshold of 5% of voting rights in ABIVAX, according to a letter received on October 1. This step, carried out indirectly through controlled entities, concerns 4,369,742 shares, or 5.64% of the capital and 5.12% of the voting rights. JP Morgan Prime Inc., JP Morgan Securities LLC, and JP Morgan Securities plc own these shares through various third-party depository receipts and cash-settled equity swaps. This crossing follows an increase in the number of shares held through assimilation, in accordance with articles of the French Commercial Code and the AMF regulations.